Home › Funds › Caligan Partners LP › TNGX
Caligan Partners LP position in TNGX
TANGO THERAPEUTICS INC · Health Care
Caligan Partners LP reported holding 2,501,246 shares of TNGX (TANGO THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$62.4M, representing 3.82% of its reported portfolio and ranking #6 among its reported holdings. Caligan Partners LP has disclosed TNGX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Caligan Partners LP's TNGX position evolved
Caligan Partners LP first disclosed a stake in TNGX in Q4 2025 at 3,729,895 shares (US$33.0M). The position peaked in Q2 2026 at 2,500,103 shares, worth US$78.2M. Across 4 filings, Caligan Partners LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 2,501,246 shares valued at US$62.4M. Notable position changes include a 35% trim in Q1 2026 (shares rose 49% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 3.73M | $33.05M | New |
| Q1 2026 | 2.41M | $50.39M | Reduce |
| Q2 2026 | 2.50M | $78.15M | Add |
| Q3 2026 | 2.50M | $62.41M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TNGX and 13F data
TNGX (TANGO THERAPEUTICS INC) is a Health Care company. 63 other funds we track also report a position in TNGX — the largest reported positions include Farallon Capital Management (US$383.8M), RTW INVESTMENTS, LP (US$350.5M), Boxer Capital Management, LLC (US$262.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TNGX
- Farallon Capital Management 12.28M sh · $383.78M · Q2 2026
- RTW INVESTMENTS, LP 14.05M sh · $350.51M · Q3 2026
- Boxer Capital Management, LLC 10.53M sh · $262.63M · Q3 2026
- Paradigm Biocapital Advisors LP 6.96M sh · $173.69M · Q3 2026
- Siren, L.L.C. 6.78M sh · $169.26M · Q3 2026
- TCG Crossover Management, LLC 6.77M sh · $168.99M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 5.18M sh · $129.24M · Q3 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 4.55M sh · $113.54M · Q3 2026
- Deep Track Capital, LP 4.50M sh · $112.28M · Q3 2026
- PERCEPTIVE ADVISORS LLC 2.69M sh · $67.19M · Q3 2026
- Seven Fleet Capital Management LP 2.23M sh · $55.71M · Q3 2026
- Logos Global Management LP 2.15M sh · $53.64M · Q3 2026
More on Caligan Partners LP
FAQ
How long has Caligan Partners LP held TNGX?
Caligan Partners LP has disclosed TNGX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Caligan Partners LP's current position in TNGX?
As of Q3 2026, Caligan Partners LP holds 2.50M shares of TNGX (TANGO THERAPEUTICS INC), valued at $62.41M, representing 3.82% of its reported portfolio and ranking #6.
Has Caligan Partners LP been buying or selling TNGX?
In the latest 13F filing (Q3 2026), Caligan Partners LP held unchanged its position in TNGX. The position peaked in Q2 2026 at 2.50M shares.
Which other funds hold TNGX?
Other major institutional holders of TNGX include Farallon Capital Management, RTW INVESTMENTS, LP, Boxer Capital Management, LLC, among 63 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.